Last reviewed · How we verify
Diltiazem Injectable Product
Diltiazem is a non-dihydropyridine calcium channel blocker that inhibits calcium influx into cardiac and vascular smooth muscle cells, reducing heart rate and blood pressure.
Diltiazem Injectable Product is a calcium channel blocker used primarily for acute management of cardiovascular conditions such as atrial fibrillation and hypertension. It has been studied in several Phase 3 and 4 trials, demonstrating efficacy and safety in emergency settings. The drug is not currently FDA-approved but has off-label use supported by clinical evidence.
At a glance
| Generic name | Diltiazem Injectable Product |
|---|---|
| Sponsor | Virginia Commonwealth University |
| Drug class | Non-dihydropyridine calcium channel blocker |
| Target | L-type voltage-gated calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Diltiazem blocks L-type calcium channels in the sinoatrial and atrioventricular nodes, slowing conduction and reducing heart rate. It also causes vasodilation of coronary and peripheral arteries by blocking calcium entry into vascular smooth muscle, thereby reducing myocardial oxygen demand and improving coronary blood flow. The injectable formulation provides rapid onset for acute management of arrhythmias and hypertensive episodes.
Approved indications
- Atrial fibrillation with rapid ventricular response
- Paroxysmal supraventricular tachycardia
- Hypertensive crisis
- Angina pectoris
Common side effects
- Hypotension
- Bradycardia
- Dizziness
- Headache
- Flushing
- Asystole or severe AV block
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diltiazem Injectable Product CI brief — competitive landscape report
- Diltiazem Injectable Product updates RSS · CI watch RSS
- Virginia Commonwealth University portfolio CI